Korean biohealth companies are moving beyond product showcases and export consultations toward clinical and technical validation with U.S. healthcare institutions. The Korea Trade-Investment Promotion Agency (KOTRA) held a two-day partnership event with Mayo Clinic and Destination Medical Center (DMC) beginning August 26, bringing together around 120 Korean medical, healthcare and home-technology companies.
The significance of the event extends beyond the participation of a globally recognized hospital. It created a pathway connecting Korean companies with the clinical data, expert validation, regulatory planning and hospital workflows needed to enter the U.S. healthcare market—areas that remain major barriers for medical AI and digital health companies.
According to KOTRA, South Korea’s biohealth exports reached a record $16.1 billion in the first half of this year, up 17.5% from a year earlier. Korean companies also accounted for approximately 12.5% of the winners in the digital health category at the CES 2026 Innovation Awards. While their product-development capabilities have advanced rapidly, many still need stronger clinical evidence and greater experience navigating overseas regulatory and commercialization processes.
From technology exports to clinical validation
Representatives from Mayo Clinic’s innovation organizations and DMC, a public-private initiative supporting the medical industry ecosystem in Rochester, Minnesota, joined the partnership event. KOTRA organized the program with the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the Korea Medical Devices Industry Association and the Integrated Healthcare Association.
The partnership focused on clinical validation, technology demonstration, joint development and potential entry into the U.S. market. Rather than treating Mayo Clinic solely as a prospective customer, the program positioned the institution as part of the validation infrastructure needed to move Korean technologies closer to clinical use.
Mayo Clinic Platform supports the development and validation of AI-enabled medical technologies using de-identified longitudinal clinical data and expertise across clinical, technical and business fields. Its Mayo Clinic Platform_Accelerate initiative offers several pathways based on a company’s development stage and needs.
The 30-week accelerator provides access to de-identified clinical data, one-on-one technical assistance and guidance from specialists in clinical practice, regulation and commercialization. According to Mayo Clinic Platform, 51 companies have graduated from the program, while 30% of alumni have continued collaborating with Mayo Clinic. Mayo Clinic Platform
The Waypoints Program, operated by Mayo Clinic Business Development, connects participating companies with Mayo Clinic clinicians and relevant departments for approximately 12 weeks. The process is designed to define clinical and technical validation projects, including the target patient population, intended clinical setting and evidence required before broader deployment.
On the first day of the event, Mayo Clinic and DMC introduced their innovation and corporate support programs. The second day featured one-on-one consultations between 35 Korean companies and representatives from the two organizations. Discussions covered clinical application, joint research, technology validation and U.S. commercialization.
Global hospitals emerge as validation infrastructure
Four Korean companies identified through last year’s inaugural program, including musculoskeletal AI company EverEx, are currently receiving support from Mayo Clinic clinicians and relevant departments. Their projects are focused on assessing clinical applicability and designing technical validation processes.
The cooperation reflects a broader shift in the role of major healthcare institutions. Hospitals are increasingly participating not only as final purchasers of medical technology but also as validation partners that help determine whether a product fits actual clinical needs and workflows.
This role is particularly important for medical AI. An algorithm that performs well on Korean data must still demonstrate comparable reliability and safety across U.S. patient populations and clinical environments. Access to de-identified clinical data, evaluation by local medical professionals and validation within real-world workflows can help narrow the gap between algorithmic performance and clinical adoption.
Participation in a Mayo Clinic program or consultation, however, does not by itself constitute U.S. regulatory approval or guarantee hospital deployment. The practical outcome of the initiative will depend less on the number of participating companies than on whether the projects produce clearly defined validation studies and lead to regulatory evidence, joint research, local demonstrations or commercial agreements.
KOTRA plans to continue its cooperation with Mayo Clinic and DMC while strengthening connections with Korean and international venture capital and other funding institutions. If this framework develops into a sustained pipeline, the U.S. competitiveness of K-biohealth companies will increasingly be determined not only by the quality of individual technologies, but also by their ability to build clinical evidence and integrate products into local healthcare systems.
